Evelo Biosciences Statistics
Total Valuation
Evelo Biosciences has a market cap or net worth of 9,491. The enterprise value is 16.70 million.
| Market Cap | 9,491 |
| Enterprise Value | 16.70M |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evelo Biosciences has 18.98 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 18.98M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +211.61% |
| Owned by Insiders (%) | 0.41% |
| Owned by Institutions (%) | 0.00% |
| Float | 16.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.20 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.23 |
Financial Position
The company has a current ratio of 0.48
| Current Ratio | 0.48 |
| Quick Ratio | 0.43 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.46 |
| Interest Coverage | -11.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -83.25% |
| Return on Capital (ROIC) | -124.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.25M |
| Employee Count | 66 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.31% in the last 52 weeks. The beta is 1.60, so Evelo Biosciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.60 |
| 52-Week Price Change | -99.31% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.02 |
| Relative Strength Index (RSI) | 49.89 |
| Average Volume (20 Days) | 2,319 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -71.24M |
| Pretax Income | -81.44M |
| Net Income | -82.35M |
| EBITDA | -69.67M |
| EBIT | -71.24M |
| Earnings Per Share (EPS) | -9.65 |
Balance Sheet
The company has 17.26 million in cash and 33.95 million in debt, giving a net cash position of -16.69 million or -0.88 per share.
| Cash & Cash Equivalents | 17.26M |
| Total Debt | 33.95M |
| Net Cash | -16.69M |
| Net Cash Per Share | -0.88 |
| Equity (Book Value) | -26.71M |
| Book Value Per Share | -1.42 |
| Working Capital | -20.83M |
Cash Flow
In the last 12 months, operating cash flow was -73.70 million and capital expenditures -287,000, giving a free cash flow of -73.99 million.
| Operating Cash Flow | -73.70M |
| Capital Expenditures | -287,000 |
| Free Cash Flow | -73.99M |
| FCF Per Share | -3.90 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Evelo Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -133.76% |
| Shareholder Yield | -133.76% |
| Earnings Yield | -1,929,519.00% |
| FCF Yield | -779,525.21% |
Stock Splits
The last stock split was on June 30, 2023. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jun 30, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |